These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21971225)

  • 21. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
    Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
    [No Abstract]   [Full Text] [Related]  

  • 23. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
    Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
    JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
    [No Abstract]   [Full Text] [Related]  

  • 24. Thalidomide and lenalidomide in the treatment of multiple myeloma.
    Kumar S; Rajkumar SV
    Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism of immunomodulatory drugs in multiple myeloma.
    Sedlarikova L; Kubiczkova L; Sevcikova S; Hajek R
    Leuk Res; 2012 Oct; 36(10):1218-24. PubMed ID: 22727252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanism of action of immunomodulatory agents in multiple myeloma.
    Reske T; Fulciniti M; Munshi NC
    Med Oncol; 2010 Jun; 27 Suppl 1(Suppl 1):S7-13. PubMed ID: 20405248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents.
    Michot C; Guillot B; Dereure O
    Dermatology; 2010; 220(1):49-50. PubMed ID: 19907136
    [No Abstract]   [Full Text] [Related]  

  • 28. Despite potential side effects, two drugs make a comeback.
    Bjorn G
    Nat Med; 2008 Mar; 14(3):226. PubMed ID: 18323826
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential new risks of lenalidomide.
    Gertz MA; Buadi FK
    Leuk Lymphoma; 2014 Sep; 55(9):1962-3. PubMed ID: 24304420
    [No Abstract]   [Full Text] [Related]  

  • 30. [Thalidomide treatment in multiple myeloma].
    Hattori Y
    Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
    [No Abstract]   [Full Text] [Related]  

  • 31. Multiple myeloma patient care: treatment options and nursing considerations.
    McGee L
    ONS Connect; 2007; 22(8 Suppl):67-8. PubMed ID: 17824572
    [No Abstract]   [Full Text] [Related]  

  • 32. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide and dexamethasone: therapy for multiple myeloma.
    Kumar S; Rajkumar SV
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):759-66. PubMed ID: 16221046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide, a thalidomide derivative, shows promise in various applications.
    Oestreicher P
    ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
    [No Abstract]   [Full Text] [Related]  

  • 37. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New drugs for multiple myeloma.
    Anderson KC
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):592-4. PubMed ID: 17099617
    [No Abstract]   [Full Text] [Related]  

  • 39. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs.
    Milrod CJ; Blevins F; Hughes D; Lerner A; Sarosiek S; Sanchorawala V; Sloan JM
    Blood; 2021 May; 137(21):2987-2989. PubMed ID: 33728443
    [No Abstract]   [Full Text] [Related]  

  • 40. Recent advances of IMiDs in cancer therapy.
    Li S; Gill N; Lentzsch S
    Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.